Jefferies analyst Andrew Tsai initiates coverage on Bright Minds Biosciences Inc. (NASDAQ: DRUG) with a Buy rating and a price ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage